Voclosporin for Lupus Nephritis: Efficacy & Safety Insights from AURORA 1 & 2 Trials

Join Jessica Farrell, PharmD, professor at the Albany College of Pharmacy and Health Sciences and clinical pharmacist at Albany Medical Center, as she breaks down the pivotal AURORA 1 and AURORA 2 clinical trials evaluating voclosporin for lupus nephritis. Learn how this second-generation calcineurin inhibitor demonstrated superior renal outcomes, including higher complete and partial renal response rates and faster time to improvement compared to placebo.

Jessica discusses the long-term safety and efficacy findings from AURORA 2, highlighting the sustained renal benefits, lower risk of renal flares, and the drug’s manageable safety profile over three years of treatment. She also addresses key trial limitations, the significance of steroid reduction, and the need for further long-term data.

For more expert insights on rheumatology treatments and lupus nephritis management, visit RhAPP.org and explore the RhAPP ACE App.